Global Maraburg Hemorrhagic Fever Market, By Drug Classification (Antiemetic, Nitroglycerin, Loperamide, Antibiotics, Others), Route of Administration (Injectable, Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Maraburg Hemorrhagic Fever Market Analysis and Size
Marburg virus refer to the type of virus that belongs to the genus marburgvirus in the family filoviridae. This virus causes a severe hemorrhagic fever that is known as global marburg hemorrhagic fever (MHF), in both humans and nonhuman primates. MHF is generally characterized by systemic viral replication, abnormal inflammatory responses and immunosuppression, similar to Ebola hemorrhagic fever. The surge in the number of people suffering from marburg hemorrhagic fever across the globe acts as one of the major factors driving the growth of global marburg hemorrhagic fever market.
Data Bridge Market Research analyses that the global maraburg hemorrhagic fever market which was USD 90.74 million in 2022, would rocket up to USD 139.25 million by 2030, and is expected to undergo a CAGR of 5.5% during the forecast period. “Hospitals” dominates the end-users segment of the market owing to the availability of highly qualified physicians. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Drug Classification (Antiemetic, Nitroglycerin, Loperamide, Antibiotics, Others), Route of Administration (Injectable, Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Amicus Therapeutics, Inc. (U.S.), Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (U.S.), Takeda Pharmaceutical Company Limited (Japan), Vertex Pharmaceuticals Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Amgen Inc. (U.S.), ELITechGroup (U.S.), GW Pharmaceuticals plc. (U.K.), Pfizer Inc. (U.S.), PerkinElmer Inc (U.S.), AutoGenomics (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BioMarin (U.S.), Sarepta Therapeutics (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Marburg Hemorrhagic Fever (MHF) is a rare but severe viral disease caused by the marburg virus, which belongs to the filoviridae family. MHF is characterized by a rapid onset of symptoms, including high fever, headache, malaise, muscle aches, and gastrointestinal symptoms, followed by hemorrhagic manifestations, such as bleeding from multiple organs.
Global Maraburg Hemorrhagic Fever Market Dynamics
Drivers
- Increasing Prevalence
The rising prevalence of maraburg hemorrhagic fever globally is a significant driver for the market. Improved diagnostic techniques, increased awareness, and better access to healthcare services have contributed to identifying more cases, leading to a larger patient population.
- Global Health Emergencies
MHF outbreaks or the occurrence of other similar infectious diseases can lead to global health emergencies, prompting increased attention and resources toward finding effective treatments for MHF. These emergencies may trigger funding allocation, research initiatives, and regulatory support for the development and availability of MHF-specific therapies.
Opportunities
- Development of Novel Antiviral Therapies
The development of novel antiviral therapies specifically targeting MHF could present a significant opportunity. Companies involved in antiviral drug discovery and development could focus on identifying and advancing compounds that inhibit the replication of the marburg virus. Such therapies could potentially reduce morbidity and mortality rates associated with MHF.
- Vaccine Development
The absence of an approved vaccine for MHF highlights a significant opportunity in this area. Companies specializing in vaccine research and development could invest in the creation of safe and effective vaccines against MHF. This could involve the use of novel vaccine platforms, such as viral vectors or mRNA-based technologies, to induce a protective immune response.
Restraint/Challenge
- Lack of Standard Cure
The lack of treatments for viral hemorrhagic fever is expected to hamper the growth of the market. The treatment is costly due to the lack of FDA-approved drugs, leading to lower affordability. No current treatment can cure viral hemorrhagic fevers and immunizations exist for only two of the many viral hemorrhagic fever. These factors can impede market growth and pose barriers for market players in the forecast period from 2023 to 2030.
- High Generic Influx
The patent expiry of most of the drugs has surfaced the way for the entry of generics into the market. The extreme use of generic medicine can hamper the demand for branded drugs, thus affecting the market.
This maraburg hemorrhagic fever market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the maraburg hemorrhagic fever Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Maraburg Hemorrhagic Fever Market Scope
The global maraburg hemorrhagic fever Market is segmented on the basis of drug classification, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Classification
- Antiemetic
- Nitroglycerin
- Loperamide
- Antibiotics
- Others
Route of Administration
- Injectable
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Maraburg Hemorrhagic Fever Market Regional Analysis/Insights
The global maraburg hemorrhagic fever market is analysed and market size insights and trends are provided by country, drug classification, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the fever marburg hemorrhagic fever market due to the advanced medical care system and infrastructure within the region.
Asia-Pacific is expected to witness high growth during the forecast period because of the large target population in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global maraburg hemorrhagic fever market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global maraburg hemorrhagic fever market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global maraburg hemorrhagic fever Market. The data is available for historic period from 2010 to 2020.
Competitive Landscape and Maraburg Hemorrhagic Fever Market Share Analysis
The global maraburg hemorrhagic fever market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global maraburg hemorrhagic fever market.
Some of the major players operating in the global maraburg hemorrhagic fever market are
- Amicus Therapeutics, Inc. (U.S.)
- Alexion Pharmaceuticals, Inc. (U.S.)
- Sanofi (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Vertex Pharmaceuticals Incorporated (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Amgen Inc. (U.S.)
- ELITechGroup (U.S.)
- GW Pharmaceuticals plc. (U.K.)
- Pfizer Inc. (U.S.)
- PerkinElmer Inc (U.S.)
- AutoGenomics (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BioMarin (U.S.)
- Sarepta Therapeutics (U.S.)
SKU-